Journal Article

DKFZ-2026-01014

http://join2-wiki.gsi.de/foswiki/pub/Main/Artwork/join2_logo100x88.png Re-Exposure of a PD-1 Inhibitor After Previous Immune-Related Adverse Events.

Burghaus-Zhang, J.DKFZ* ; Schulz, C.DKFZ* ; Ramelyte, E. ; Mangana, J. ; Özistanbullu, D. ; Kleemann, J. ; Enk, A.DKFZ* ; Hassel, J.DKFZ*

2026
Multimed Toronto, Ontario

Abstract: Programmed cell death protein (ligand) 1 (PD-(L)1) inhibitors are well established in the treatment of dermatological tumors. Mostly, they are well tolerated, but in about 9-21% of patients, grade 3/4 immune-related adverse events (irAEs) occur. As treatment options are limited, it is of interest to determine whether readministration of another or the same PD-(L)1 inhibitor is safe.This is a multicenter, retrospective study on patients with metastasized dermatological tumors who were retreated with either the same or a different PD-(L)1 inhibitor after the development of irAEs. The study was conducted at centers in Heidelberg, Zurich, and Frankfurt.22 patients were included between April 2020 and December 2022 with a median age of 71 years. A total of 13 (59%) patients were re-exposed with the same antibody and nine (41%) received a different PD-(L)1 inhibitor. Six (46%) of the patients who were re-exposed to the same antibody had an irAE, of which 67% were identical with the first. In patients receiving a different PD-(L)1 inhibitor, four (44%) developed an irAE, of which 75% were identical with the first.Both an intraclass switch of PD-(L)1 inhibitor treatment and re-exposure with the same antibody after an irAE can be considered as options with a fair chance of improving therapy tolerance.

Keyword(s): Humans (MeSH) ; Aged (MeSH) ; Male (MeSH) ; Female (MeSH) ; Retrospective Studies (MeSH) ; Immune Checkpoint Inhibitors: adverse effects (MeSH) ; Immune Checkpoint Inhibitors: therapeutic use (MeSH) ; Middle Aged (MeSH) ; Aged, 80 and over (MeSH) ; Programmed Cell Death 1 Receptor: antagonists & inhibitors (MeSH) ; Skin Neoplasms: drug therapy (MeSH) ; immune-related adverse events ; immunotherapy ; skin cancer ; Immune Checkpoint Inhibitors ; Programmed Cell Death 1 Receptor

Note: #NCTZFB9#

---

Contributing Institute(s):

1. Koordinierungsstelle NCT Heidelberg (HD02)

Research Program(s):

1. 899 - ohne Topic (POF4-899) (POF4-899)

Appears in the scientific report 2026

---

Database coverage:
; ; ; ; Article Processing Charges ; Clarivate Analytics Master Journal List ; DOAJ Seal ; Ebsco Academic Search ; Essential Science Indicators ; Fees ; IF < 5 ; JCR ; SCOPUS ; Science Citation Index Expanded ; Web of Science Core Collection

---